TFF Pharmaceuticals has announced the initiation of Phase 1 trial of its dry powder voriconazole, which the company is developing for the treatment of invasive pulmonary aspergillosis (IPA). The Phase I SAD/MAD study will be conducted in Canada and will enroll a total of 64 healthy subjects, 32 in each part.
The company recently raised $22 million in an initial public offering, with funds primarily going toward development of the voriconazole inhalation powder and its dry powder tacrolimus.
TFF Pharmaceuticals CEO Glenn Mattes said, “TFF Pharmaceuticals has been able to rapidly progress from research, to product formulation, to clinical trial study for our lead drug candidate, voriconazole inhalation powder. This is a key milestone for our company and further validation of the viability and innovation of our patented TFF technology. We are committed to developing new drugs with potentially numerous commercial applications for chronic respiratory diseases and lung conditions, as well as other non-lung related diseases.”
Read the TFF Pharmaceuticals press release.
